New biotech cAMPfield emerges with $180M to reshape IBD treatment
BioSpace
Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.
pharminent
June 18, 2026 (Last updated: June 19, 2026)
BioSpace
Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.
